医药行业周报（2024年第48周）

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [4]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.4% during the week of November 18-22, 2024, ranking 22nd among 31 sectors in the Shenwan classification, outperforming the Shenzhen Composite Index and the CSI 300 but underperforming the Shanghai Composite Index and the Wind All A Index [1][10]. - The total transaction volume for the pharmaceutical sector during this week was 423.16 billion yuan [10]. Summary by Sections Industry Overview - The pharmaceutical sector's performance was characterized by a 2.4% decline, with the chemical pharmaceutical sub-sector showing a smaller drop of 1.2%. Other sub-sectors such as pharmaceutical commerce, medical devices, biological products, traditional Chinese medicine II, and medical services saw declines ranging from 2.2% to 4.5% [12][16]. Industry News and Important Announcements - The National Healthcare Security Administration issued a guideline for the pricing of radiological examination services, consolidating existing price projects into 26 items for provincial healthcare bureaus to reference [18]. - A new policy aims to expand the types of medications available in grassroots healthcare institutions to better meet public demand for chronic and common disease treatments [19]. - The integration of artificial intelligence in diagnostic services has been officially recognized, allowing hospitals to choose between training medical staff or utilizing AI without incurring additional charges [23]. - The first IDH dual-target inhibitor, Vorasidenib, has been introduced in China, marking a significant advancement in treatment options for patients with specific types of tumors [24]. - The first HIF-2α inhibitor, Belzutifan, has been approved for use in China, providing new treatment options for patients with Von Hippel-Lindau disease-related cancers [25]. Important Announcements - Heng Rui Medicine received approval to conduct clinical trials for HRS-6208 capsules, a new selective small molecule inhibitor [28]. - Tian Tan Biology completed phase III clinical trials for a subcutaneous immunoglobulin product, showing effectiveness in maintaining stable IgG levels [29]. - Life Science Pharmaceuticals received approval for the market entry of arginine perindopril, a drug used for hypertension and heart failure [30]. - Boji Medicine obtained two invention patents related to cardiovascular disease treatments and non-small cell lung cancer models [31]. - Meikang Biology received a medical device registration certificate for diagnostic test kits, enhancing its product line in the in vitro diagnostic sector [32].